Red Light Holland Partners with Arizona State University to Support Groundbreaking Psychedelic Genome Project (PGP) Research Study
- Partnership with prestigious Arizona State University enhances company's scientific credibility
- Research could lead to development of personalized psychedelic medicine protocols
- Leverages existing infrastructure and customer base in Netherlands for study support
- Positions company as a leader in evidence-based psychedelic research
- None.
Toronto, Ontario--(Newsfile Corp. - June 19, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable law, is pleased to announce its partnership with Arizona State University to support Dr. Candace Lewis, PhD's research study titled "Psychedelic Genome Project – Genomic regulators of psilocybin response."
This groundbreaking research aims to advance understanding of the effects of psilocybin on genetic expression and improve nutrition-driven health outcomes. The study is particularly significant given the growing legalization landscape for psychedelics globally and the potential for developing future novel screening methods that could revolutionize personalized psychedelic medicine.
Red Light Holland will provide comprehensive support for the study through multiple strategic initiatives:
Recruitment Support: The Company will distribute approved research materials to customers through its subsidiaries in the Netherlands, feature the study prominently on its website and client portal, include study information in monthly newsletters and e-communications, and share promotional content across all social media channels. Additionally, Red Light Holland's licensed therapists who offer free consultations to clients will actively refer eligible participants to the screening process.
Sample Collection Kit Management: Red Light Holland will coordinate the delivery of saliva collection kits directly to participants who complete eligibility screening and provide informed consent. The Company will track all kit distributions and returns with detailed record-keeping and provide weekly progress updates on participant enrollment and kit distribution status.
Ongoing Collaboration: The partnership includes staff training sessions to ensure proper study protocols, customization of materials to align with customer communication standards, regular check-ins to monitor study progress, and support for robust enrollment through established client relationships and trust networks.
"We are enthusiastic about partnering with Arizona State University to support this groundbreaking research, understanding how psilocybin affects epigenetic regulation of gene expression is a huge missing piece in our understanding of psychedelics that could bring about many breakthroughs," commented Shashkes, CTIO of Red Light Holland.
"We're excited to launch this national collaboration between the Psychedelic Genome Project and Red Light Holland to investigate how psilocybin affects the epigenome," said Dr. Candace Lewis, Assistant Professor at Arizona State University and Director of the BEAR Lab. "By identifying biological signatures of response, we hope to lay the foundation for more precise and effective psychedelic therapies in the future."
Todd Shapiro, CEO and Director of Red Light Holland, commented, "This partnership with Arizona State University represents a significant milestone in advancing psychedelic research and personalized medicine. By leveraging our products, infrastructure and customer relationships in the Netherlands, we can contribute meaningful support to Dr. Lewis's groundbreaking genome research. This collaboration exemplifies our commitment to scientific advancement and positions Red Light Holland as a leader in supporting evidence-based psychedelic research that could transform how we understand and utilize these powerful compounds for therapeutic benefit."
About Red Light Holland
Red Light Holland is an Ontario-based corporation engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws.
For additional information on the Company:
Todd Shapiro
Chief Executive Officer & Director
Tel: 647-643-TRIP (8747)
Email: todd@redlight.co
Website: www.RedLight.co
About Arizona State University And Dr. Candace Lewis
Arizona State University (ASU) is a top-ranked public research university recognized globally for its innovation, interdisciplinary scholarship, and commitment to societal impact. With a mission to advance research that serves the public good, ASU fosters groundbreaking discoveries across fields ranging from neuroscience and sustainability to engineering and the arts.
Dr. Candace Lewis is an Assistant Professor at Arizona State University, jointly appointed in the School of Life Sciences and Department of Psychology. She directs the Brain, Epigenetics, and Altered States Research (BEAR) Lab, where her team investigates how environmental experiences, from early-life adversity to psychedelic therapies, shape the brain and behavior through epigenomic mechanisms. Through interdisciplinary and translational research, Dr. Lewis and her lab are advancing precision medicine approaches for mental health at one of the nation's leading innovation universities.
For additional information on Arizona State University And Dr. Candace Lewis
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Information
Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, certain of which are beyond the control of Red Light Holland. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.
Forward-looking statements include, but are not limited to: statements with respect to the Company's ability to successfully support the Arizona State University research study; the Company's expectations regarding participant recruitment and enrollment success; statements regarding the potential benefits and outcomes of the psychedelic genome research; the Company's ability to effectively distribute research materials and collection kits; expectations regarding the coordination and management of sample collection processes; the potential impact of the research on personalized psychedelic medicine development; statements regarding the Company's role in advancing scientific understanding of psilocybin effects; the Company's ability to maintain effective collaboration with Arizona State University; expectations regarding staff training and protocol implementation; the potential for the research to revolutionize treatment approaches; statements regarding the significance of the legal availability of psilocybin truffles in the Netherlands for research purposes; the Company's ability to leverage its customer networks for research support; expectations regarding the Company's position in supporting psychedelic research; the potential for developing novel screening methods; statements regarding the growing legalization landscape for psychedelics; the Company's ability to support robust enrollment through established client relationships; expectations regarding weekly progress reporting and tracking capabilities; the potential for the research to benefit the broader psychedelic community; the Company's commitment to supporting research initiatives; statements regarding the groundbreaking nature of the research; the potential for the study to advance understanding of genetic expression effects; expectations regarding nutrition-driven health outcome improvements; the Company's ability to customize materials and coordinate logistics effectively; statements regarding the Company's enthusiasm for the partnership; the potential for the research to contribute to scientific advancement; expectations regarding the success of the collaboration; the Company's ability to provide ongoing outreach through established networks; statements regarding the Company's comprehensive support capabilities; the potential for the research to support personalized medicine approaches; the Company's expectations regarding its role in psychedelic research advancement; statements regarding the unique opportunity provided by legal psilocybin availability; the potential for the research to revolutionize psychedelic medicine; expectations regarding the Company's ability to maintain detailed record-keeping; the potential significance of the research findings; statements regarding the Company's commitment to research collaboration; the Company's ability to effectively brief staff for participant referrals; expectations regarding the coordination of training sessions; the potential for the research to advance the psychedelic industry; statements regarding the Company's established customer relationships and trust networks; the Company's ability to support high-quality data collection; expectations regarding the customization of communication materials; the potential for the research to support treatment development; statements regarding the Company's role in supporting scientific research; the Company's ability to provide comprehensive recruitment support; expectations regarding the effectiveness of digital platform utilization; the potential for the research to contribute to personalized treatment approaches.
Forward-looking information is based on a number of key expectations and assumptions made by Red Light Holland, including without limitation: the continued partnership and collaboration with Arizona State University; the Company's ability to successfully support research initiatives; the continued legal availability of psilocybin truffles in the Netherlands; the effectiveness of the Company's customer networks for research recruitment; the ability to maintain regulatory compliance throughout the research collaboration; the successful coordination of sample collection and distribution processes; the continued operation of the Company's subsidiaries in the Netherlands; the ability to effectively train staff for research protocol implementation; the maintenance of established customer relationships and trust networks; the successful customization and distribution of research materials; the ability to provide ongoing logistical support for the research study; the continued availability of licensed therapists for client consultations and referrals; the effectiveness of digital platforms and communication channels for research promotion; the ability to maintain detailed record-keeping and progress reporting capabilities; the successful coordination with Arizona State University researchers; the continued commitment to supporting scientific advancement in psychedelic research; no adverse changes in regulations affecting psychedelic research; the ability to maintain operational capacity to support research initiatives; the continued interest and participation of customers in research studies; the successful implementation of training sessions and protocol adherence; no unanticipated expenses or operational challenges related to research support; the ability to coordinate logistics effectively and securely; the continued effectiveness of established communication channels with customers; the ability to maintain comprehensive support throughout the duration of the research study.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the inability of the Company to successfully support the Arizona State University research study; the inability of the Company to effectively recruit participants for the research; the inability to maintain effective collaboration with Arizona State University; potential changes in regulations affecting psychedelic research or the Company's operations; the inability to successfully distribute or track research materials and collection kits; potential operational challenges in coordinating sample collection processes; the inability to maintain established customer relationships for research support; potential changes in the legal status of psilocybin truffles in the Netherlands; the inability to effectively train staff for research protocol implementation; potential challenges in customizing materials or coordinating logistics; the inability to provide ongoing outreach through established networks; potential difficulties in maintaining detailed record-keeping and progress reporting; the inability to coordinate training sessions or maintain protocol adherence; potential challenges in leveraging digital platforms for research promotion; the inability to maintain comprehensive support throughout the research duration; potential adverse changes in the research study requirements or protocols; the inability to effectively brief staff for participant referrals; potential challenges in maintaining operational capacity for research support; the inability to successfully coordinate with Arizona State University researchers; potential changes in customer interest or participation in research studies; the inability to maintain regulatory compliance throughout the collaboration; potential operational or financial challenges affecting research support capabilities; the inability to provide effective logistical coordination for sample collection; potential challenges in maintaining customer trust networks for research purposes; the inability to customize communication materials effectively; potential difficulties in maintaining ongoing collaboration commitments; the inability to support robust enrollment through established relationships; potential challenges in coordinating secure sample collection processes; the inability to maintain weekly progress reporting capabilities; potential adverse changes affecting the Company's subsidiaries in the Netherlands; the inability to maintain effective digital platform utilization for research support; potential challenges in supporting high-quality data collection processes; the inability to maintain comprehensive recruitment support capabilities; potential difficulties in coordinating with licensed therapists for referrals; the inability to effectively support scientific advancement through the partnership; potential changes in research requirements affecting the Company's support capabilities; the inability to maintain established communication channels with customers for research purposes; potential challenges in providing ongoing support for research initiatives; the inability to successfully coordinate training and protocol implementation; potential adverse changes in the psychedelic research landscape; the inability to maintain effective coordination of research logistics; potential challenges affecting the Company's ability to support personalized medicine research advancement.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/256114
FAQ
What is the purpose of Red Light Holland's partnership with Arizona State University?
How will Red Light Holland (TRUFF) support the ASU research study?
Who is leading the Psychedelic Genome Project at Arizona State University?
What potential impact could this research have on psychedelic medicine?
Where will Red Light Holland conduct the participant recruitment for the study?
